Celgene asserts its REVLIMID® patents against Sun Pharma under Hatch-Waxman Act
Client(s) Celgene Corporation
Jones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Sun Pharma Global FZE, Sun Pharma Global Inc., Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited in a Hatch-Waxman litigation matter involving Sun’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
Celgene Corporation v. Sun Pharma Global FZE, et al., No. 2-18-cv-11630 (D.N.J.)